| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
17α-Hydroxyprogesterone acetate targets progesterone receptors, acting as a progestogen. It possesses progestational activity. The compound also has anti-inflammatory effects at the murine maternal-fetal interface. As a synthetic progestin, it may modulate gene expression through progesterone receptor-mediated pathways. The compound's effects on the maternal-fetal interface suggest potential immunomodulatory activity. However, detailed receptor binding affinities have not been extensively characterized.
|
|---|---|
| ln Vitro |
17α-Hydroxyprogesterone (Delalutin) does not have an androgenic effect and does not affect the development of nonreproductive organs like progesterone and some other sex steroids[1].
In vitro, 17α-Hydroxyprogesterone acetate is not androgenic and, like progesterone and certain other sex steroids, does not alter the development of nonreproductive organs. The compound possesses progestational activity. It has anti-inflammatory effects. However, detailed in vitro activity data including EC₅₀ values or receptor binding affinities have not been extensively published. |
| ln Vivo |
In vivo, 17α-Hydroxyprogesterone acetate is used clinically as a progestin for various indications. It has anti-inflammatory effects at the murine maternal-fetal interface. The compound is a pharmaceutical used in clinical practice. However, specific in vivo study results are not detailed in the available literature. The compound's progestational activity is well-established through clinical use.
|
| Enzyme Assay |
In vitro assays for 17α-Hydroxyprogesterone acetate could include evaluation of progesterone receptor binding using radioligand binding assays or reporter gene assays measuring progesterone receptor-mediated transcriptional activity. Anti-inflammatory activity can be assessed by measuring cytokine production in immune cells or by evaluating effects on inflammatory signaling pathways. The compound's purity is confirmed by HPLC. Standard steroid hormone assays may be used.
|
| Cell Assay |
In vitro cellular assays for 17α-Hydroxyprogesterone acetate typically involve evaluation of progestational activity in progesterone receptor-expressing cell lines. Cells are treated with the compound and progesterone receptor-mediated gene expression is measured using reporter gene assays or qPCR. Anti-inflammatory effects can be evaluated in immune cells by measuring cytokine production. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo animal experiments for 17α-Hydroxyprogesterone acetate have been conducted in mouse models to evaluate its anti-inflammatory effects at the maternal-fetal interface. Teratogenic potential has been evaluated in mice. The compound is a pharmaceutical used in clinical practice. Detailed study protocols are not extensively detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 17α-Hydroxyprogesterone acetate are characteristic of steroid hormones. The compound has a molecular weight of 372.50 g/mol and a molecular formula of C₂₃H₃₂O₄. Melting point: 249-250°C. As a lipophilic steroid ester, it is expected to have good membrane permeability and tissue distribution. The compound is used as a pharmaceutical ingredient.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 17α-Hydroxyprogesterone acetate has been evaluated in teratogenicity studies in mice. As a progestin used in clinical practice, its safety profile is well-established from clinical use. Common adverse effects may include those associated with progestin therapy. Comprehensive toxicological data are available from the pharmaceutical literature.
|
| References |
|
| Additional Infomation |
Hydroxyprogesterone acetate is a corticosteroid hormone.
17α-Hydroxyprogesterone acetate (CAS# 302-23-8, molecular formula C₂₃H₃₂O₄, molecular weight 372.50) is a synthetic progestin and ester derivative of 17α-hydroxyprogesterone. It possesses progestational activity and has anti-inflammatory effects. Used as a pharmaceutical ingredient. No specific clinical trial information beyond existing approvals has been identified. |
| Molecular Formula |
C23H32O4
|
|---|---|
| Molecular Weight |
372.50
|
| Exact Mass |
372.23
|
| CAS # |
302-23-8
|
| PubChem CID |
10156152
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
494.3±45.0 °C at 760 mmHg
|
| Melting Point |
249-250ºC
|
| Flash Point |
213.5±28.8 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
737
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(O[C@]1(C(C)=O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O)=O
|
| InChi Key |
VTHUYJIXSMGYOQ-KOORYGTMSA-N
|
| InChi Code |
InChI=1S/C23H32O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h13,18-20H,5-12H2,1-4H3/t18-,19+,20+,21+,22+,23+/m1/s1
|
| Chemical Name |
[(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6846 mL | 13.4228 mL | 26.8456 mL | |
| 5 mM | 0.5369 mL | 2.6846 mL | 5.3691 mL | |
| 10 mM | 0.2685 mL | 1.3423 mL | 2.6846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
